drugset / Trial / NCT04993690
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Timeline
- Start
- 2021-07-06
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocbrutinib | Small molecule | 100 mg | Oral |